Lung Cancer Archives | VJOncology

The Lung Cancer Channel on VJOncology is supported by Takeda and AstraZeneca. These supporters have no influence over the production of the content.

View overview page

Next-generation ALK inhibitors: treatment sequencing and resistance

Alessandra Bearz • 6 Jun 2022

Unanswered questions regarding the use of IO in NSCLC

Jarushka Naidoo • 5 Jun 2022

Highlights in NSCLC from ASCO 2022

Jarushka Naidoo • 5 Jun 2022

Chemotherapy-free immunotherapy-based treatment approaches for NSCLC

Jarushka Naidoo • 5 Jun 2022

Optimizing precision medicine in NSCLC

Liza Villaruz • 6 Jun 2022

ASCO 2022: Highlights in lung cancer

Joshua K. Sabari • 3 Jun 2022

Assessing EFGR TKIs in patients with wild-type EFGR NSCLC

Joshua K. Sabari • 3 Jun 2022

ctDNA MRD detection in patients with NSCLC

Bruna Pellini • 5 Jun 2022

Updates in early stage non-small cell lung cancer

Alessandra Bearz • 6 Jun 2022

The role of immunotherapy with KRAS inhibitors in KRAS-driven NSCLC

Jia Luo • 3 Jun 2022

Targeting KRAS-driven NSCLC

Jia Luo • 3 Jun 2022

UK genetic profiling to identify oncogenic drivers

Matthew Krebs • 5 Jun 2022

Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutation

Matthew Krebs • 6 Jun 2022

Association of pre-existing autoimmune disease & irAEs secondary to ICI therapy

Anna Claire Olsson-Brown • 4 Jun 2022

Current treatment strategies KRASG12C–mutated NSCLC

Liza Villaruz • 6 Jun 2022

Ascertaining the mechanisms of resistance to KRASG12C inhibitors

Liza Villaruz • 6 Jun 2022

1
2
3
Next